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Conversion of endothelial cells into 
mesenchymal stem-like cells
Medici et al., Nat Med 2010; 16: 1400–1406; doi:10.1038/nm.2252
Transformation of epithelial cells into mesenchymal cells (epithe-
lial-to-mesenchymal transition (EMT)) is critical during embryo-
genesis, wound healing, organ fibrosis, and tumor metastasis. 
Endothelial-to-mesenchymal transition (EndMT) occurs in the 
embryo during endocardial cushion formation, and during adult 
life this process generates carcinoma-associated fibroblasts, as well 
as many fibroblasts during cardiac and renal fibrosis. Subjects with 
fibrodysplasia ossificans progressiva (FOP), a disease in which acute 
inflammation causes heterotopic ossification in soft tissues and for-
mation of an ectopic skeleton, have an activating mutation in the 
gene encoding activin-like kinase-2 (ALK2), a bone morphogenetic 
protein (BMP) type I receptor. Ossification in FOP lesions begins 
with a mesenchymal condensation, followed by chondrogenesis 
and endochondral ossification; the source of the heterotopic carti-
lage and bone in these lesions is unknown. Medici et al. examined 
whether these cells could derive from endothelial cells by EndMT. 
In patients with FOP, they found that cells in chondrogenic lesions 
(SOX9 positive) and cells in osteogenic lesions (osteocalcin positive) 
also expressed the endothelial markers TIE2 and vWF (Figure). 
They confirmed this important result by inducing the heterotopic 
formation of cartilage and bone (by intramuscular injection of the 
ALK2 activator BMP4) in a reporter mouse crossed with a mouse 
carrying a Tie2-Cre transgene, hence marking all endothelial cells 
and their progeny. In vitro experiments showed that endothelial 
cells expressing ALK2 acquired a mesenchymal stem cell-like phe-
notype, displaying several stem-cell marker proteins. Indeed, these 
cells were capable of differentiating toward osteogenic, chondro-
genic, and adipogenic fates, indicating that their differentiation 
potential was similar to that of bone marrow mesenchymal stem 
cells. In additional experiments they found that ALK2 is an abso-
lute requirement for EndMT and showed that transforming growth 
factor-β2 (TGF-β2) and BMP4 stimulate EndMT, but BMP7 and 
VEGF inhibit it.
In sum, this interesting study shows that EndMT generates cells 
that are like mesenchymal stem cells, that this process is medi-
ated by ALK2 upon stimulation by TGF-β2 or BMP4, and that the 
patho logical bone formation of FOP is the result of EndMT.
Juan Oliver
LFA-1-specific therapy prolongs 
allograft survival in primates
Badell et al., J Clin Invest 2010; 120: 4520–4531; doi:10.1172/JCI43895
T cells have a central role in initiating allograft rejection, and immu-
nosuppressive therapies that selectively target molecules critical for 
their activation may inhibit allograft rejection while reducing the 
side effects associated with other immunosuppressive therapies. 
Activation of naive T cells requires binding of T-cell receptors to 
donor antigen (signal 1) of either self or allogeneic major histocom-
patibility complex molecules, a subsequent costimulatory signal 
(signal 2), and soluble factors, such as cytokines, which deliver addi-
tional stimuli (signal 3) to augment the T-cell response. This three-
signal model of naive-T-cell activation has served as a useful model 
to develop therapeutic strategies for allograft rejection. However, 
it was recently recognized that non-naive, or memory, T cells (TM 
cells) cells have much less demanding requirements for activation, 
and approaches to limit deployment of T cells with prior antigen 
experience are needed. One potential candidate to control TM cell-
mediated rejection is the adhesion molecule lymphocyte function-
associated antigen 1 (LFA-1), a β2 integrin heterodimer, composed 
of a unique α-chain (CD11a) and a shared β-chain (CD18) that 
primarily binds ICAM-1. Indeed, LFA-1 was recently implicated in 
the programming of CD8+ T-cell memory via ICAM-1 on dendritic 
cells, and therapy with the LFA-1-specific monoclonal antibody 
(mAb) efalizumab is effective in controlling the T cell-mediated 
autoimmune disease psoriasis. Further, LFA-1-specific mAbs have 
been shown to prolong graft survival in rodents with allogeneic and 
xenogeneic transplants, but little experience in primates is available. 
Accordingly, Badell et al. examined TS-1/22, a mouse anti-human 
CD11a mAb, and characterized the role of LFA-1 blockade in rhe-
sus monkey alloimmune and viral-specific responses. First, they 
found that LFA-1 was increasingly expressed on TM cells. They then 
tested TS-1/22-based regimens (short-term treatment, i.e., induc-
tion therapy) in combination with either basiliximab (an IL-2Rα-
specific mAb) and sirolimus or belatacept (a high-affinity variant 
of the CD28 costimulation blocker CTLA4Ig) and found that they 
prolonged islet allograft survival. Moreover, TS-1/22 masked LFA-1 
on TM cells in vivo and inhibited the generation of alloproliferative 
and cytokine-producing effector T cells that expressed high levels 
of LFA-1 in vitro.
This study supports the use of LFA-1-specific induction therapy 
to neutralize costimulation blockade-resistant populations of T cells 
and suggests that additional studies on LFA-1-specific therapies in 
organ transplantation are needed.
Juan Oliver
Immunohistochemistry of chondrogenic (first and third columns) and 
osteogenic (second and fourth columns) lesions from individuals with 
FOP with activating ALK2 mutations (bottom). Normal cartilage and 
bone are shown in the top.
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Selective vitamin D receptor 
activation with paricalcitol  
for reduction of albuminuria  
in patients with type 2 diabetes
De Zeeuw et al., Lancet 2010; 376: 1543–1551; doi:10.1016/S0140-
6736(10)61032-X
Despite treatment with renin–angiotensin–aldosterone system 
(RAAS) inhibitors, patients with diabetes still have an increased 
risk of progressive renal failure that correlates with albuminuria. 
De Zeeuw et al. investigated whether paricalcitol could be used to 
reduce albuminuria in patients with diabetic nephropathy in a mul-
tinational, placebo-controlled, double-blind trial of 281 patients with 
type 2 diabetes and albuminuria who were receiving angiotensin-
converting enzyme inhibitors or angiotensin receptor blockers. The 
primary end point was the percentage change in geometric mean 
urinary albumin-to-creatinine ratio (UACR) from baseline to last 
measurement during treatment (24 weeks) for the combined parical-
citol groups (1 µg paricalcitol (n = 93) or 2 µg paricalcitol (n = 95)) 
versus the placebo group (Figure). The authors showed that 24 weeks’ 
treatment with 2 µg paricalcitol daily reduced residual albuminuria 
in patients with type 2 diabetic nephropathy who were on stable 
doses of angiotensin-converting enzyme inhibitors or angiotensin 
receptor blockers, particularly in those with high dietary sodium 
intake. By contrast, the reduction in UACR in the 1-µg paricalcitol 
group was not significant. In addition to lowering albuminuria, 2 
µg paricalcitol also lowered systolic blood pressure and estimated 
glomerular filtration rate (eGFR). All effects occurred within 4 
weeks, the reduction in UACR and eGFR was fairly stable during the 
treatment phase, and measurements returned toward baseline after 
drug withdrawal, indicating that the effects were real and reversible. 
No effect of paricalcitol on circulating aldosterone concentrations 
or plasma renin activity over 24 weeks was observed. The authors 
attribute the decrease in eGFR to an increase in serum creatinine 
due to an effect of vitamin D on creatinine metabolism. Incidence 
of hypercalcemia, adverse events, and serious adverse events was 
similar between groups receiving paricalcitol versus placebo.
The study is limited by the use of albuminuria as a surrogate 
marker of progression, and the fact that true glomerular filtration 
rate, ambulatory blood pressure, and pretreatment vitamin status 
were not measured. In summary, this first randomized controlled 
trial indicates that addition of 2 µg/d paricalcitol to RAAS inhibi-
tion safely lowers residual albuminuria in patients with diabetic 
nephropathy and could be a novel approach to lower residual renal 
risk in diabetes.
Marc De Broe
Coronary microvascular function in 
early chronic kidney disease
Charytan et al., Circ Cardiovasc Imaging 2010; 3: 663–671; doi:10.1161/
CIRCIMAGING.110.957761
It is well known that people with chronic kidney disease (CKD) 
have a greater prevalence of atherosclerotic disease. Much spec-
ulation has been focused on whether this prevalence is caused 
by the comorbidities that resulted in CKD or by CKD itself. 
In a retrospective study, Charytan et al. used two measures of 
myocardial blood flow to examine its association with CKD and 
other factors. The researchers examined perfusion tests at base-
line and 1 year for 435 people with mild to moderate CKD but 
without diabetes mellitus. Coronary flow reserve (CFR) is the 
maximum increase in blood flow through the coronary arteries 
at which stress should cause the vascular resistance of the coro-
nary arteries to decrease. At baseline, CFR (the ratio of stress to 
rest perfusion) was associated with creatinine clearance (CrCl). 
For every positive difference of 10 ml/min among individuals, 
the CFR was greater, a significant association seen in univari-
ate analyses. When controlled for sex, low-density lipoprotein 
(LDL) cholesterol, and mean blood pressure, the relationship 
was only marginally significant. And when controlled for age, 
sex, LDL cholesterol, mean blood pressure, smoking, body mass 
index, ethnicity, and the presence of a stress defect, this relation-
ship between CFR and CrCl was no longer significant. After one 
year of follow-up in the cohort overall, the CFR did not change 
significantly among groups, based on the presence or absence of 
mild or moderate kidney disease. In unadjusted analyses, those 
with greater CrCl had only a trend toward a lesser decline in 
CFR. However, when adjusted for factors significantly associated 
with a change in CFR (such as LDL, age, sex, ethnicity, smok-
ing, body mass index, the presence or absence of a stress defect, 
and mean blood pressure), the relationship between CrCl and 
change in CFR was significant. Patients with lower CrCl had a 
greater decline in CFR over time.
This study suggests that the presence of functional changes in 
coronary circulation may be related to the comorbidities that bring 
about kidney disease, but the accelerated nature of the decline can 
be attributed to some aspect of the CKD milieu. Although the 
clinical significance of these findings has not been fully described, 
their relevance in periods of recurrent hemodynamic stress such 
as dialysis treatments must be considered.
Lynda Szczech
Change in UACR from baseline to last measurement during treatment. 
Error bars represent 95% confidence intervals. P values are for the 
comparison of paricalcitol versus placebo.
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